TABLE 2.
Comparison of disulfiram MICs and MBCs to other test agents against S. aureus
| Variant and straina | Test agentb | Concn (μg/ml) |
MBC:MIC | |
|---|---|---|---|---|
| MIC | MBC | |||
| MSSA NCTC 8325/RN1 | THM | 8 | 32 | 4:1 |
| DSF | 16 | >64 | >4:1 | |
| DDTC | 32 | 64 | 2:1 | |
| OXA | ≤0.5 | |||
| VAN | 1 | 2 | 2:1 | |
| CA-MRSA CA-347 | THM | 2 | 32 | 16:1 |
| DSF | 16 | >64 | >4:1 | |
| DDTC | 32 | 64 | 2:1 | |
| OXA | >64 | |||
| VAN | 1 | 1 | 1:1 | |
| HA-MRSA COL | THM | 2 | 16 | 8:1 |
| DSF | 8 | 64 | 8:1 | |
| DDTC | 16 | 64 | 4:1 | |
| OXA | >64 | |||
| VAN | 2 | 4 | 2:1 | |
| LRSA SA LinR #14 | THM | 4 | 32 | 8:1 |
| DSF | 8 | 64 | 8:1 | |
| DDTC | 16 | >64 | >4:1 | |
| OXA | >64 | |||
| VAN | 1 | 2 | 2:1 | |
| hVISA Mu3 ATCC 700698 | THM | 2 | 32 | 16:1 |
| DSF | 32 | >64 | >2:1 | |
| DDTC | 32 | >64 | >2:1 | |
| OXA | >64 | |||
| VAN | 2 | 4 | 2:1 | |
| VISA AR-215 | THM | 2 | 16 | 8:1 |
| DSF | 16 | >64 | >4:1 | |
| DDTC | 64 | |||
| OXA | >64 | |||
| VAN | 4 | 8 | 2:1 | |
| VRSA HIP11714 | THM | 2 | 16 | 8:1 |
| DSF | 16 | 64 | 4:1 | |
| DDTC | 32 | >64 | >2:1 | |
| OXA | >64 | |||
| VAN | >64 | |||
a
MSSA, methicillin-susceptible S. aureus; CA-MRSA, community-acquired methicillin-resistant S. aureus; HA-MRSA, hospital-acquired methicillin-resistant S. aureus; LRSA, linezolid-resistant S. aureus; hVISA, heterogeneous-resistant vancomycin-intermediate S. aureus; VISA, vancomycin-intermediate S. aureus; VRSA, vancomycin-resistant S. aureus.
b
THM, thiram; DSF, disulfiram; DDTC, sodium diethyldithiocarbamate trihydrate; OXA, oxacillin; VAN, vancomycin.